$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx

$cnbx Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000168316823004890 Filed on July 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$100.0K	$310.2K	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$168.3K	$220.1K	$386.0K
YoY Change	-46.54%	-42.96%	207.75%
% of Gross Profit
Research & Development	$93.24K	$263.1K	$249.1K
YoY Change	-43.01%	5.64%	-54.79%
% of Gross Profit
Depreciation & Amortization	$38.49K	$39.99K	$48.83K
YoY Change	-18.61%	-18.1%	-12.71%
% of Gross Profit
Operating Expenses	$261.5K	$483.3K	$635.0K
YoY Change	-45.33%	-23.9%	-6.1%
Operating Profit		-$173.1K	-$635.0K
YoY Change		-72.74%	-6.1%
Interest Expense	-$412.1K	$18.39K	-$46.65K
YoY Change	30422.96%	-139.42%	-92.8%
% of Operating Profit
Other Income/Expense, Net		$18.39K	-$46.65K
YoY Change		-139.43%
Pretax Income	-$573.6K	-$154.7K	-$681.7K
YoY Change	19.56%	-77.31%	-48.51%
Income Tax
% Of Pretax Income
Net Earnings	-$573.6K	-$154.7K	-$681.7K
YoY Change	19.56%	-77.31%	-48.51%
Net Earnings / Revenue	-573.55%	-49.87%
Basic Earnings Per Share		-$0.02	-$0.05
Diluted Earnings Per Share	-$0.02	-$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	17.03M shares	4.966M shares	1.239M shares
Diluted Shares Outstanding		9.266M shares	1.239M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$129.7K	$44.15K	$96.28K
YoY Change	10.36%	-54.14%	-95.11%
Cash & Equivalents	$129.7K	$44.15K	$96.28K
Short-Term Investments
Other Short-Term Assets	$94.61K	$304.7K	$137.8K
YoY Change	17.14%	121.05%	-13.12%
Inventory
Prepaid Expenses			$137.8K
Receivables
Other Receivables
Total Short-Term Assets	$224.3K	$348.8K	$234.1K
YoY Change	13.12%	49.0%	-88.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$274.7K	$313.2K	$492.2K
YoY Change	-37.1%	-36.36%	-29.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$239.5K
YoY Change	-100.0%	-100.0%	-75.59%
Other Assets
YoY Change
Total Long-Term Assets	$274.7K	$313.2K	$731.6K
YoY Change	-55.17%	-57.19%	-56.32%
TOTAL ASSETS
Total Short-Term Assets	$224.3K	$348.8K	$234.1K
Total Long-Term Assets	$274.7K	$313.2K	$731.6K
Total Assets	$499.0K	$662.0K	$965.7K
YoY Change	-38.48%	-31.45%	-74.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$335.9K	$1.015M	$319.6K
YoY Change	-27.15%	217.67%	65.47%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$1.344M	$1.333M	$1.605M
YoY Change	-23.6%	-16.97%	52.39%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.516M	$2.571M	$2.148M
YoY Change	2.98%	19.7%	46.14%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.516M	$2.571M	$2.148M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.516M	$2.571M	$2.148M
YoY Change	2.98%	19.7%	46.14%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.26M	-$23.69M	-$20.07M
YoY Change	18.06%	18.02%
Common Stock	$2.261K	$1.603K	$124.00
YoY Change	1723.39%	1192.74%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$2.017M	-$1.909M	-$1.182M
YoY Change
Total Liabilities & Shareholders Equity	$499.0K	$662.0K	$965.7K
YoY Change	-38.48%	-31.45%	-74.6%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$573.6K	-$154.7K	-$681.7K
YoY Change	19.56%	-77.31%	-48.51%
Depreciation, Depletion And Amortization	$38.49K	$39.99K	$48.83K
YoY Change	-18.61%	-18.1%	-12.71%
Cash From Operating Activities	$20.52K	-$18.59K	-$375.4K
YoY Change	-113.72%	-95.05%	-39.08%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	65.03K	14.99K	240.0K
YoY Change	-56.61%	-93.75%	-80.8%
NET CHANGE
Cash From Operating Activities	20.52K	-18.59K	-375.4K
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	65.03K	14.99K	240.0K
Net Change In Cash	85.55K	-3.600K	-135.4K
YoY Change	227.9%	-97.34%	-121.35%
FREE CASH FLOW
Cash From Operating Activities	$20.52K	-$18.59K	-$375.4K
Capital Expenditures	$0.00	$0.00	$0.00
Free Cash Flow	$20.52K	-$18.59K	-$375.4K
YoY Change	-113.83%	-95.05%	-39.08%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001343009
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-05-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-52403
	dei	Entity Registrant Name EntityRegistrantName	CNBX PHARMACEUTICALS INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5644005
	dei	Entity Address Address Line1 EntityAddressAddressLine1	#3 Bethesda Metro Center
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 700
	dei	Entity Address City Or Town EntityAddressCityOrTown	Bethesda
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20814
	dei	City Area Code CityAreaCode	(877)
	dei	Local Phone Number LocalPhoneNumber	424-2429
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	17033732	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	44151	usd
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	117515	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	304645	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	80772	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	348796	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	198287	usd
CY2023Q2	us-gaap	Investments Investments	0	usd
CY2022Q3	us-gaap	Investments Investments	176087	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	313223	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	436792	usd
CY2023Q2	us-gaap	Assets Assets	662019	usd
CY2022Q3	us-gaap	Assets Assets	811166	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1015240	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	461128	usd
CY2023Q2	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1332577	usd
CY2022Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1758702	usd
CY2023Q2	CNBX	Due To Related Party DueToRelatedParty	223645	usd
CY2022Q3	CNBX	Due To Related Party DueToRelatedParty	223645	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2571462	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	2443475	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16033732	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16033732	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1257927	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1257927	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1603	usd
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	124	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18646026	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	18031869	usd
CY2023Q2	us-gaap	Other Additional Capital OtherAdditionalCapital	3459510	usd
CY2022Q3	us-gaap	Other Additional Capital OtherAdditionalCapital	3459510	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-330933	usd
CY2022Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2574846	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23685648	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-20548968	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1909442	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1632311	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	662019	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	811166	usd
CY2023Q2	us-gaap	Revenues Revenues	310165	usd
CY2022Q2	us-gaap	Revenues Revenues	0	usd
	us-gaap	Revenues Revenues	310165	usd
	us-gaap	Revenues Revenues	0	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	263115	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	249061	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	338330	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1019682	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	220132	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	385945	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	741716	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1455935	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	483247	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	635006	usd
	us-gaap	Operating Expenses OperatingExpenses	1080046	usd
	us-gaap	Operating Expenses OperatingExpenses	2475617	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-173082	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-635006	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-769881	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2475617	usd
CY2023Q2	CNBX	Capital Loss CapitalLoss	0	usd
CY2022Q2	CNBX	Capital Loss CapitalLoss	0	usd
	CNBX	Capital Loss CapitalLoss	-2395298	usd
	CNBX	Capital Loss CapitalLoss	0	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18392	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-46646	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	28499	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-767926	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-154690	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-681652	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3136680	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	42261	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-59870	usd
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-605740	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-154690	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-639392	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3196550	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3849283	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.65
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.65
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9265865	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1238826	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4030048	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1221478	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9265865	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1238826	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4030048	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1221478	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1632311	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	470131	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	145505	usd
	CNBX	Realization Of Available For Sale Asset RealizationOfAvailableForSaleAsset	2243913	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3136680	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1909442	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2011531	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	221804	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	34975	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-154690	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1909442	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	1805914	usd
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	225289	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	635587	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-605740	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1182493	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-648028	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	104926	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	42261	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-681652	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-1182493	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3136680	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3243543	usd
	us-gaap	Depreciation Depreciation	123569	usd
	us-gaap	Depreciation Depreciation	151239	usd
	CNBX	Interest On Loans InterestOnLoans	0	usd
	CNBX	Interest On Loans InterestOnLoans	0	usd
	CNBX	Capital Loss1 CapitalLoss1	-2395298	usd
	CNBX	Capital Loss1 CapitalLoss1	-0	usd
	CNBX	Due To Related Party Cash Flow DueToRelatedPartyCashFlow	0	usd
	CNBX	Due To Related Party Cash Flow DueToRelatedPartyCashFlow	0	usd
	CNBX	Royalties Receivables Valuation RoyaltiesReceivablesValuation	0	usd
	CNBX	Royalties Receivables Valuation RoyaltiesReceivablesValuation	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	CNBX	Profit From Held For Trading Investments ProfitFromHeldForTradingInvestments	0	usd
	CNBX	Profit From Held For Trading Investments ProfitFromHeldForTradingInvestments	0	usd
	CNBX	Convertible Loan Valuation ConvertibleLoanValuation	9033	usd
	CNBX	Convertible Loan Valuation ConvertibleLoanValuation	718392	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	145505	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	635587	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	223873	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-66560	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	554110	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	142083	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133038	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1529682	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	24702	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	-0	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	513	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24702	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-513	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	34972	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	240000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34972	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	240000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	0	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-73364	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1290195	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	117515	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1386472	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	44151	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	96277	usd
	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	470131	usd
	CNBX	Exercise Of Convertible Loan To Shares Of Common Stock. ExerciseOfConvertibleLoanToSharesOfCommonStock.	225287	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3136680	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-23685648	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	338330	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1019682	usd
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84E_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zUUqa55GzM8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i><span id="xdx_86A_zF3BNP3gbMxa">Reclassifications</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain amounts in the prior period financial statements have been reclassified to conform to the current period presentation. These reclassifications had no effect on reported losses, total assets, or stockholders’ equity as previously reported.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p>
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	900000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000	shares
	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	14795073	shares
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	470131	usd
	CNBX	Monthly Operating Lease Expense MonthlyOperatingLeaseExpense	6500	usd

Files In Submission

Name	View Source	Status
0001683168-23-004890-index-headers.html	Edgar Link	pending
0001683168-23-004890-index.html	Edgar Link	pending
0001683168-23-004890.txt	Edgar Link	pending
0001683168-23-004890-xbrl.zip	Edgar Link	pending
cnbx-20230531.xsd	Edgar Link	pending
cnbx_ex3101.htm	Edgar Link	pending
cnbx_ex3102.htm	Edgar Link	pending
cnbx_ex3201.htm	Edgar Link	pending
cnbx_ex3202.htm	Edgar Link	pending
cnbx_i10q-053123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
cnbx-20230531_cal.xml	Edgar Link	unprocessable
cnbx-20230531_def.xml	Edgar Link	unprocessable
cnbx-20230531_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cnbx_i10q-053123_htm.xml	Edgar Link	completed
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cnbx-20230531_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx

2023 Q3 Form 10-Q Financial Statement

#000168316823004890 Filed on July 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX CNBX Pharmaceuticals Inc Stock $cnbx

2023 Q3 Form 10-Q Financial Statement

#000168316823004890 Filed on July 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CNBX
CNBX Pharmaceuticals Inc Stock $cnbx